CPRX
Catalyst Pharmaceuticals, Inc.
Price Chart
Latest Quote
$25.00
Current Price| Previous Close | $24.30 |
| Open | $24.23 |
| Day High | $25.13 |
| Day Low | $24.20 |
| Volume | 1,177,396 |
Stock Information
| Shares Outstanding | 122.91M |
| Total Debt | $2.89M |
| Cash Equivalents | $689.89M |
| Revenue | $578.20M |
| Net Income | $217.56M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.07B |
| P/E Ratio | 14.62 |
| EPS (TTM) | $1.71 |
| Exchange | NCM |
📊 Custom Metrics & Score
Score: 35/42| Debt to Equity | 0.00 |
| Debt to Earnings | 0.01 |
| Current Ratio | 5.17 |
| Quick Ratio | 4.83 |
| Avg Revenue Growth | 62.29% |
| Profit Margin | 33.33% |
| Return on Equity | 22.52% |
| Avg FCF Growth | 75.78% |
| FCF Yield | 7.79% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $25.00 | 1,177,396 |
| 2026-01-30 | $24.30 | 972,100 |
| 2026-01-29 | $24.58 | 922,900 |
| 2026-01-28 | $24.20 | 912,900 |
| 2026-01-27 | $24.07 | 780,800 |
| 2026-01-26 | $23.99 | 1,492,900 |
| 2026-01-23 | $23.58 | 1,314,700 |
| 2026-01-22 | $24.45 | 992,900 |
| 2026-01-21 | $24.13 | 943,400 |
| 2026-01-20 | $23.38 | 1,620,500 |
| 2026-01-16 | $22.70 | 892,800 |
| 2026-01-15 | $22.96 | 1,096,900 |
| 2026-01-14 | $23.17 | 1,889,800 |
| 2026-01-13 | $22.35 | 1,925,700 |
| 2026-01-12 | $23.22 | 1,044,100 |
| 2026-01-09 | $22.72 | 1,374,400 |
| 2026-01-08 | $22.60 | 1,359,100 |
| 2026-01-07 | $22.72 | 1,381,800 |
| 2026-01-06 | $22.58 | 1,352,100 |
| 2026-01-05 | $22.80 | 1,403,500 |
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
📰 Latest News
2 Under-the-Radar Biotech Stocks Set to Boom in 2026
Motley Fool • 2026-01-24T19:20:00Z
Catalyst Pharmaceuticals, Inc. (CPRX): A Bull Case Theory
Insider Monkey • 2026-01-19T22:18:20Z
Jim Cramer on Catalyst Pharmaceuticals: “It’s a Very Inexpensive Stock”
Insider Monkey • 2026-01-16T17:13:24Z
Does Forbes’ Small-Cap Honor for Sales Growth Reshape the Bull Case For Catalyst Pharmaceuticals (CPRX)?
Simply Wall St. • 2026-01-09T20:15:56Z
CPRX or DSNKY: Which Is the Better Value Stock Right Now?
Zacks • 2026-01-09T16:40:02Z
Is Catalyst Pharmaceuticals (CPRX) Still Attractive After Recent Share Price Pause?
Simply Wall St. • 2026-01-09T09:10:16Z
Is Catalyst Pharmaceuticals (CPRX) Stock Undervalued Right Now?
Zacks • 2026-01-08T14:40:04Z
Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says
MT Newswires • 2026-01-07T16:21:14ZCatalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move?
Motley Fool • 2025-12-31T16:26:03Z
Assessing Catalyst Pharma After 600% Surge and Rare Disease Expansion in 2025
Simply Wall St. • 2025-12-18T16:18:40Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $68,448,000 | $51,651,000 | $34,252,000 | $21,692,000 |
| Cost Of Revenue | $68,845,000 | $51,967,000 | $34,393,000 | $21,884,000 |
| Total Revenue | $491,734,000 | $398,204,000 | $214,203,000 | $140,833,000 |
| Operating Revenue | $491,734,000 | $398,204,000 | $214,203,000 | $140,833,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $296,610,000 | $311,392,000 | $112,365,000 | $88,448,000 |
| Other Income Expense | $5,075,000 | $3,024,000 | $2,881,000 | $282,000 |
| Net Non Operating Interest Income Expense | $16,064,000 | $4,675,000 | - | - |
| Total Other Finance Cost | $-16,064,000 | $-4,675,000 | - | - |
| Operating Expense | $227,765,000 | $259,425,000 | $77,972,000 | $66,564,000 |
| Selling And Marketing Expense | $111,344,000 | $86,689,000 | $29,469,000 | $26,151,000 |
| General And Administrative Expense | $66,396,000 | $47,021,000 | $28,714,000 | $23,477,000 |
| Other Non Operating Income Expenses | - | $7,699,000 | $2,881,000 | $282,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $163,889,000 | $71,410,000 | $83,079,000 | $39,482,000 |
| Net Interest Income | $16,064,000 | $4,675,000 | - | - |
| Normalized Income | $160,042,150 | $69,123,856 | $83,079,000 | $39,482,000 |
| Net Income From Continuing And Discontinued Operation | $163,889,000 | $71,410,000 | $83,079,000 | $39,482,000 |
| Total Operating Income As Reported | $195,124,000 | $86,812,000 | $101,838,000 | $52,385,000 |
| Net Income Common Stockholders | $163,889,000 | $71,410,000 | $83,079,000 | $39,482,000 |
| Net Income | $163,889,000 | $71,410,000 | $83,079,000 | $39,482,000 |
| Net Income Including Noncontrolling Interests | $163,889,000 | $71,410,000 | $83,079,000 | $39,482,000 |
| Net Income Continuous Operations | $163,889,000 | $71,410,000 | $83,079,000 | $39,482,000 |
| Pretax Income | $216,263,000 | $94,511,000 | $104,719,000 | $52,667,000 |
| Operating Income | $195,124,000 | $86,812,000 | $101,838,000 | $52,385,000 |
| Depreciation Amortization Depletion Income Statement | $37,377,000 | $32,565,000 | $1,098,000 | $0 |
| Depreciation And Amortization In Income Statement | $37,377,000 | $32,565,000 | $1,098,000 | $0 |
| Amortization Of Intangibles Income Statement | $37,377,000 | $32,565,000 | $1,098,000 | $0 |
| Gross Profit | $422,889,000 | $346,237,000 | $179,810,000 | $118,949,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $1.31 | $0.63 | $0.75 | $0.37 |
| Basic EPS | $1.38 | $0.67 | $0.80 | $0.38 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $1,228,150 | $737,856 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $227,823,000 | $116,669,000 | $103,077,000 | $52,577,000 |
| Total Unusual Items | $5,075,000 | $3,024,000 | - | - |
| Total Unusual Items Excluding Goodwill | $5,075,000 | $3,024,000 | - | - |
| Reconciled Depreciation | $37,774,000 | $32,881,000 | $1,239,000 | $192,000 |
| EBITDA (Bullshit earnings) | $232,898,000 | $119,693,000 | $103,077,000 | $52,577,000 |
| EBIT | $195,124,000 | $86,812,000 | $101,838,000 | $52,385,000 |
| Diluted Average Shares | $124,943,603 | $113,753,154 | $111,375,631 | $107,795,585 |
| Basic Average Shares | $118,457,673 | $106,279,736 | $103,374,606 | $103,379,349 |
| Diluted NI Availto Com Stockholders | $163,889,000 | $71,410,000 | $83,079,000 | $39,482,000 |
| Tax Provision | $52,374,000 | $23,101,000 | $21,640,000 | $13,185,000 |
| Gain On Sale Of Security | $5,075,000 | $3,024,000 | - | - |
| Amortization | $37,377,000 | $32,565,000 | $1,098,000 | $0 |
| Research And Development | $12,648,000 | $93,150,000 | $19,789,000 | $16,936,000 |
| Selling General And Administration | $177,740,000 | $133,710,000 | $57,085,000 | $49,628,000 |
| Other Gand A | $45,924,000 | $34,252,000 | $22,536,000 | $19,015,000 |
| Salaries And Wages | $20,472,000 | $12,769,000 | $6,178,000 | $4,462,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $570,960,000 | $193,832,000 | $267,950,000 | $206,831,000 |
| Total Assets | $851,411,000 | $470,114,000 | $375,630,000 | $237,788,000 |
| Total Non Current Assets | $227,802,000 | $250,785,000 | $54,824,000 | $27,682,000 |
| Non Current Deferred Assets | $45,982,000 | $36,544,000 | $18,736,000 | $23,697,000 |
| Non Current Deferred Taxes Assets | $45,982,000 | $36,544,000 | $18,736,000 | $23,697,000 |
| Goodwill And Other Intangible Assets | $156,672,000 | $194,049,000 | $32,471,000 | $0 |
| Other Intangible Assets | $156,672,000 | $194,049,000 | $32,471,000 | - |
| Current Assets | $623,609,000 | $219,329,000 | $320,806,000 | $210,106,000 |
| Other Current Assets | $1,030,000 | $351,000 | $354,000 | $327,000 |
| Prepaid Assets | $19,998,000 | $12,046,000 | $4,813,000 | $3,919,000 |
| Inventory | $19,541,000 | $15,644,000 | $6,805,000 | $7,870,000 |
| Receivables | $65,487,000 | $53,652,000 | $10,793,000 | $6,724,000 |
| Other Receivables | $11,000 | $138,000 | $354,000 | $105,000 |
| Accounts Receivable | $65,476,000 | $53,514,000 | $10,439,000 | $6,619,000 |
| Cash Cash Equivalents And Short Term Investments | $517,553,000 | $137,636,000 | $298,395,000 | $191,266,000 |
| Cash And Cash Equivalents | $517,553,000 | $137,636,000 | $298,395,000 | $171,445,000 |
| Non Current Prepaid Assets | - | - | $9,000 | $9,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $3,188,000 | $3,557,000 | $3,894,000 | $4,202,000 |
| Long Term Debt And Capital Lease Obligation | $2,786,000 | $3,188,000 | $3,557,000 | $3,894,000 |
| Current Debt And Capital Lease Obligation | $402,000 | $369,000 | $337,000 | $308,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $123,779,000 | $82,233,000 | $75,209,000 | $30,957,000 |
| Total Non Current Liabilities Net Minority Interest | $3,101,000 | $6,170,000 | $17,621,000 | $3,894,000 |
| Other Non Current Liabilities | $315,000 | $485,000 | $14,064,000 | - |
| Tradeand Other Payables Non Current | $0 | $2,497,000 | $14,064,000 | $0 |
| Current Liabilities | $120,678,000 | $76,063,000 | $57,588,000 | $27,063,000 |
| Other Current Liabilities | $417,000 | $465,000 | $238,000 | $243,000 |
| Payables And Accrued Expenses | $109,113,000 | $66,346,000 | $51,881,000 | $22,477,000 |
| Interest Payable | $389,000 | $1,031,000 | $0 | $0 |
| Payables | $21,069,000 | $28,064,000 | $25,804,000 | $2,847,000 |
| Other Payable | $3,582,000 | $12,540,000 | $13,127,000 | - |
| Total Tax Payable | $894,000 | $729,000 | $8,702,000 | $79,000 |
| Income Tax Payable | $894,000 | $729,000 | $8,702,000 | $79,000 |
| Accounts Payable | $16,593,000 | $14,795,000 | $3,975,000 | $2,768,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $727,632,000 | $387,881,000 | $300,421,000 | $206,831,000 |
| Total Equity Gross Minority Interest | $727,632,000 | $387,881,000 | $300,421,000 | $206,831,000 |
| Stockholders Equity | $727,632,000 | $387,881,000 | $300,421,000 | $206,831,000 |
| Gains Losses Not Affecting Retained Earnings | $64,000 | $14,000 | $24,000 | $-148,000 |
| Other Equity Adjustments | $64,000 | $14,000 | $24,000 | $-148,000 |
| Retained Earnings | $285,161,000 | $121,272,000 | $49,862,000 | $-26,310,000 |
| Long Term Equity Investment | $21,564,000 | $16,489,000 | $0 | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $120,879,099 | $107,121,549 | $105,263,031 | $102,992,913 |
| Share Issued | $120,879,099 | $107,121,549 | $105,263,031 | $102,992,913 |
| Tangible Book Value | $570,960,000 | $193,832,000 | $267,950,000 | $206,831,000 |
| Invested Capital | $727,632,000 | $387,881,000 | $300,421,000 | $206,831,000 |
| Working Capital | $502,931,000 | $143,266,000 | $263,218,000 | $183,043,000 |
| Capital Lease Obligations | $3,188,000 | $3,557,000 | $3,894,000 | $4,202,000 |
| Total Capitalization | $727,632,000 | $387,881,000 | $300,421,000 | $206,831,000 |
| Additional Paid In Capital | $442,286,000 | $266,488,000 | $250,430,000 | $233,186,000 |
| Capital Stock | $121,000 | $107,000 | $105,000 | $103,000 |
| Common Stock | $121,000 | $107,000 | $105,000 | $103,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $2,786,000 | $3,188,000 | $3,557,000 | $3,894,000 |
| Current Capital Lease Obligation | $402,000 | $369,000 | $337,000 | $308,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $10,746,000 | $8,883,000 | $5,132,000 | $4,035,000 |
| Current Accrued Expenses | $88,044,000 | $38,282,000 | $26,077,000 | $19,630,000 |
| Investments And Advances | $21,564,000 | $16,489,000 | $0 | - |
| Net PPE | $3,584,000 | $3,703,000 | $3,617,000 | $3,976,000 |
| Accumulated Depreciation | $-1,120,000 | $-723,000 | $-406,000 | $-275,000 |
| Gross PPE | $4,704,000 | $4,426,000 | $4,023,000 | $4,251,000 |
| Leases | $991,000 | $991,000 | $980,000 | $980,000 |
| Other Properties | $2,230,000 | $2,508,000 | $2,770,000 | $3,017,000 |
| Machinery Furniture Equipment | $1,483,000 | $927,000 | $273,000 | $254,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $9,578,000 | $9,161,000 | $1,262,000 | $929,000 |
| Work In Process | $3,445,000 | $4,573,000 | $5,543,000 | $5,172,000 |
| Raw Materials | $6,518,000 | $1,910,000 | $0 | $1,769,000 |
| Treasury Shares Number | - | $0 | - | - |
| Dueto Related Parties Non Current | - | - | $14,064,000 | $0 |
| Dueto Related Parties Current | - | - | $13,127,000 | $0 |
| Other Short Term Investments | - | - | $0 | $19,821,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $239,252,000 | $61,856,000 | $116,018,000 | $59,351,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $239,808,000 | $143,600,000 | $116,047,000 | $60,372,000 |
| Cash Flow From Continuing Operating Activities | $239,808,000 | $143,600,000 | $116,047,000 | $60,372,000 |
| Operating Gains Losses | - | $262,000 | $762,000 | $292,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-556,000 | $-81,744,000 | $-29,000 | $-1,021,000 |
| Investing Cash Flow | $-556,000 | $-293,502,000 | $9,209,000 | $-11,021,000 |
| Cash Flow From Continuing Investing Activities | $-556,000 | $-293,502,000 | $9,209,000 | $-11,021,000 |
| Net Other Investing Changes | - | $-198,293,000 | $-10,000,000 | - |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-296,000 | $0 | $0 | $-12,089,000 |
| Issuance Of Capital Stock | $141,000,000 | $0 | $0 | - |
| Financing Cash Flow | $140,665,000 | $-10,857,000 | $1,694,000 | $-8,143,000 |
| Cash Flow From Continuing Financing Activities | $140,665,000 | $-10,857,000 | $1,694,000 | $-8,143,000 |
| Net Other Financing Charges | $-13,554,000 | $-13,649,000 | $-7,875,000 | $-153,000 |
| Net Common Stock Issuance | $140,704,000 | $0 | $0 | $-12,089,000 |
| Common Stock Issuance | $141,000,000 | $0 | $0 | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Paid Supplemental Data | $1,395,000 | $705,000 | $0 | $0 |
| Income Tax Paid Supplemental Data | $68,451,000 | $50,458,000 | $7,667,000 | $3,000,000 |
| End Cash Position | $517,553,000 | $137,636,000 | $298,395,000 | $171,445,000 |
| Beginning Cash Position | $137,636,000 | $298,395,000 | $171,445,000 | $130,237,000 |
| Changes In Cash | $379,917,000 | $-160,759,000 | $126,950,000 | $41,208,000 |
| Proceeds From Stock Option Exercised | $13,515,000 | $2,792,000 | $9,569,000 | $4,099,000 |
| Common Stock Payments | $-296,000 | $0 | $0 | $-12,089,000 |
| Net Investment Purchase And Sale | $0 | $-13,465,000 | $19,238,000 | $-10,000,000 |
| Sale Of Investment | $0 | $0 | $19,238,000 | $0 |
| Purchase Of Investment | $0 | $-13,465,000 | $0 | $-10,000,000 |
| Net Intangibles Purchase And Sale | $0 | $-81,513,000 | $0 | $0 |
| Purchase Of Intangibles | $0 | $-81,513,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-556,000 | $-231,000 | $-29,000 | $-1,021,000 |
| Purchase Of PPE | $-556,000 | $-231,000 | $-29,000 | $-1,021,000 |
| Change In Working Capital | $30,914,000 | $-37,324,000 | $13,729,000 | $5,022,000 |
| Change In Other Current Liabilities | $-369,000 | $-338,000 | $-307,000 | $864,000 |
| Change In Payables And Accrued Expense | $55,646,000 | $16,620,000 | $17,598,000 | $4,032,000 |
| Change In Accrued Expense | $53,848,000 | $5,800,000 | $16,391,000 | $5,520,000 |
| Change In Payable | $1,798,000 | $10,820,000 | $1,207,000 | $-1,488,000 |
| Change In Account Payable | $1,798,000 | $10,820,000 | $1,207,000 | $-1,488,000 |
| Change In Prepaid Assets | $-8,504,000 | $-5,792,000 | $-807,000 | $3,977,000 |
| Change In Inventory | $-3,897,000 | $-4,739,000 | $1,065,000 | $-3,219,000 |
| Change In Receivables | $-11,962,000 | $-43,075,000 | $-3,820,000 | $-632,000 |
| Changes In Account Receivables | $-11,962,000 | $-43,075,000 | $-3,820,000 | $-632,000 |
| Other Non Cash Items | $-557,000 | $83,225,000 | $4,394,000 | $287,000 |
| Stock Based Compensation | $22,251,000 | $14,250,000 | $7,907,000 | $6,073,000 |
| Unrealized Gain Loss On Investment Securities | $-5,075,000 | $-3,024,000 | $0 | $0 |
| Deferred Tax | $-9,388,000 | $-17,818,000 | $4,937,000 | $9,316,000 |
| Deferred Income Tax | $-9,388,000 | $-17,818,000 | $4,937,000 | $9,316,000 |
| Depreciation Amortization Depletion | $37,774,000 | $32,881,000 | $1,239,000 | $192,000 |
| Depreciation And Amortization | $37,774,000 | $32,881,000 | $1,239,000 | $192,000 |
| Amortization Cash Flow | $37,377,000 | $32,565,000 | $1,098,000 | $0 |
| Amortization Of Intangibles | $37,377,000 | $32,565,000 | $1,098,000 | $0 |
| Depreciation | $397,000 | $316,000 | $141,000 | $192,000 |
| Net Income From Continuing Operations | $163,889,000 | $71,410,000 | $83,079,000 | $39,482,000 |
| Gain Loss On Sale Of PPE | - | $262,000 | $247,000 | $292,000 |
| Gain Loss On Investment Securities | - | - | $762,000 | - |